June 20, 2021

Medical Trend

Medical News and Medical Resources


Warning: sprintf(): Too few arguments in /www/wwwroot/medicaltrend.org/wp-content/themes/newsphere/lib/breadcrumb-trail/inc/breadcrumbs.php on line 254

Analysis of 15-year sales data of antibody drugs (2006~2020)

10 min read

Analysis of 15-year sales data of antibody drugs (2006~2020)


Analysis of 15-year sales data of antibody drugs (2006~2020).   Recently, with the gradual release of the annual reports of major companies, the author has compiled the latest sales data of 61 foreign antibody drugs in 2020 and other annual data.

Analysis of 15-year sales data of antibody drugs (2006~2020)

 

These drugs are divided into 9 categories and are briefly analyzed and shared as follows:


1. “The King of Medicine”

Adalimumab (trade name Humira), an anti-TNFα fully human IgG1κ monoclonal antibody, was approved for marketing on December 31, 2002. Its indications are rheumatoid arthritis and other autoimmune diseases. The sellers are AbbVie (Abbott) and Japan Eisai (Eisai).

After approval, the sales increased to USD 5 billion in the 7th year (2009), USD 10 billion in the 11th year (2013), and USD 15 billion in the 14th year (2016). In recent years It has always ranked first in the sales of antibody drugs, and has continued to be the king of drugs. In the past three years, the annual sales have been around 20 billion US dollars, reaching the platform.

In the 15 years from 2006 to 2020, the accumulated sales amounted to 172.4 billion U.S. dollars, and the average annual sales return was as high as 11.5 billion U.S. dollars, as shown in Figure 1.


2. “The King of Kings”

Pembrolizumab (trade name Keytruda), anti-PD-1 humanized IgG4κ monoclonal antibody, was approved for marketing on September 4, 2014. Its indication is melanoma and other tumor diseases. The seller is Merck.

In the fifth year (2019) after approval, sales exceeded 10 billion U.S. dollars (Humira used 11 years), and in the sixth year (2020) it reached 14.38 billion U.S. dollars (Humira used 13 years), with rapid growth , Set a record, created a miracle, can be described as the “king of kings”, see Figure 2.

In the six years from 2015 to 2020, it has accumulated sales of 38.4 billion US dollars, with an average annual sales of 6.4 billion US dollars, an average annual growth of 488%.

 


3. “King Fried”

In addition to the drug king Humira, the five “veteran” super blockbuster star antibody drugs, Etanercept, Infliximab, Rituximab, Bevacizumab, and Trastuzumab, have been ranked TOP10 in the global annual best-selling drug list for 10 years, forming a “king bomb”. After the glorious ten-year heyday of Life-cycle, the splendid spring line was imprinted, as shown in Figure 3.

1) Etanercept

The trade name is Enbrel, a recombinant TNFαR-Fc fusion protein. It was approved for marketing on November 2, 1998. Its indications are rheumatoid arthritis and other autoimmune diseases. The vendors are Amgen, Pfizer and Takeda.

In the 15 years from 2006 to 2020, the accumulated sales amounted to 111.7 billion U.S. dollars, and the average annual sales return was as high as 7.45 billion U.S. dollars.

2) Infliximab

The trade name is Remicade, an anti-TNFα chimeric IgG1κ monoclonal antibody. It was approved for marketing on August 24, 1998. The indication is CD (Crohn’s disease) and other autoimmune diseases. The vendors are J&J, Merck and M Tanabe.

In the 15 years from 2006 to 2020, the accumulated sales amounted to 99.7 billion U.S. dollars, and the average annual sales return was as high as 6.64 billion U.S. dollars.

3) Rituximab

Trade name Rituxan/MabThera, anti-CD20 chimeric IgG1κ monoclonal antibody, was approved for marketing on November 26, 1997. The indication is CD20-positive NHL (non-Hodgkin’s lymphoma) and other tumor diseases. The seller is Roche (Genentech). ) And Chugai.

In the 15 years from 2006 to 2020, the accumulated sales amounted to 95.4 billion U.S. dollars, with an average annual sales return of up to 6.36 billion U.S. dollars.

4) Bevacizumab

Trade name Avastin, anti-VEGF humanized IgG1κ monoclonal antibody, was approved for marketing on February 26, 2004. Its indications are metastatic colorectal cancer (mCRC) and other tumor diseases. The vendors are Roche (Genentech) and Chugai.

In the 15 years from 2006 to 2020, the accumulated sales amounted to 92.9 billion U.S. dollars, and the average annual sales return was as high as 6.19 billion U.S. dollars.

5) Trastuzumab

Trade name Herceptin, anti-HER2 humanized IgG1κ monoclonal antibody, was approved for marketing on September 25, 1998, and its indications are HER2 overexpressing metastatic breast cancer and other tumor diseases. The vendors are Roche (Genentech) and Chugai.

In the 15 years from 2006 to 2020, the accumulated sales amounted to 86.5 billion U.S. dollars, and the average annual sales return was as high as 5.77 billion U.S. dollars.

 

 

4. Newly promoted over 5 billion “super blockbuster”

1) Nivolumab

The trade name is Opdivo, an anti-PD-1 fully human IgG4κ monoclonal antibody. It was first launched in Japan on July 4, 2014. The indications are melanoma and other tumor diseases. The vendors are BMS and OnoPharmaceutical.

In the second year of listing (2016), it was promoted to a super blockbuster, and its sales in 2019 reached US$8.017 billion (Note: The 6.992 billion in 2020 in the figure is only BMS sales data).

2) Aflibercept

Trade name Eylea, a recombinant VEGFR1/2-Fc fusion protein, was approved for marketing on November 18, 2011. The indications are AMD (wet age-related macular degeneration), RVO (macular edema after retinal vein occlusion) and other ophthalmic diseases. The sellers are Sanofi (Regeneron) and Bayer.

In its fifth year of listing (2016), it was promoted to a super blockbuster, and its sales in 2019 reached 7.313 billion U.S. dollars (Note: The 4.947 billion in 2020 in the figure is only Regeneron sales data).

3) Ustekinumab

Trade name Stelara, anti-IL12/23 fully human IgG1κ monoclonal antibody, was approved for marketing on September 25, 2009. The indication is adult (≥18 years old) moderate to severe psoriasis vulgaris and other autoimmune diseases. The seller is J&J and M Tanabe.

In the ninth year of listing (2019), it has been promoted to a super blockbuster, and its sales in 2020 will reach 7.707 billion US dollars.

4) Denosumab

Trade names Prolia and Xgeva, anti-RANK-L fully human IgG2κ monoclonal antibody, approved for marketing on June 1, 2010, indications for osteoporosis/bone injury prevention in postmenopausal women, bone-related indicators for patients with bone metastases from solid tumors The sellers are Amgen and Daiichi Sankyo.

In the ninth year of listing (2019), it has been promoted to be a super blockbuster, and its sales in 2020 will reach 5.120 billion U.S. dollars.

5) Eculizumab

Trade name Soliris, anti-C5 complement humanized IgG2/4κ monoclonal antibody, approved for marketing on March 16, 2007, indications are PNH (paroxysmal nocturnal hemoglobinuria), atypical hemolytic uremic syndrome (aHUS) , The seller is Alexion.

Just promoted to super blockbuster in 2020 (the 13th year of listing), with sales of 5.141 billion U.S. dollars.

 

 

5. Upstarts in the future: products that will reach 3 billion within 5 years of listing

1) Ocrelizumab

Trade name Ocrevus, anti-CD20 humanized IgG1 monoclonal antibody (glyco-engineered antibody), was approved for marketing on March 28, 2017. The indication is Primary Progressive Multiple Sclerosis (PPMS), etc. The seller is Roche (Genentech).

In the second year (2019) after the listing, sales amounted to 3.767 billion U.S. dollars, and sales in 2020 reached 4.613 billion U.S. dollars.

2) Dupilumab

The trade name is Dupixent, an anti-IL-4Rα fully human IgG4 monoclonal antibody. It was approved for marketing on March 28, 2017. The indication is moderate to severe adult eczema (atopic dermatitis) and the seller is Sanofi (Regeneron).

In 2020 (the third year after listing), sales will reach US$4.035 billion.

3) Daratumumab

Trade name Darzalex, anti-CD38 fully human IgG1κ monoclonal antibody, was approved for marketing on November 16, 2015. The indication is multiple myeloma (the first monoclonal antibody approved for the treatment of this disease), and the seller is J&J .

In the fourth year after listing (2019), sales were 2.998 billion U.S. dollars, and sales in 2020 reached 4.190 billion U.S. dollars.

4) Secukinumab

The trade name is Cosentyx, an anti-IL-17A fully human IgG1κ monoclonal antibody. It was approved for marketing on January 21, 2015. It is indicated for immunological diseases such as moderate to severe plaque psoriasis in adults. The seller is Novartis.

In the fourth year (2019) after listing, sales will be 3.551 billion U.S. dollars, and sales in 2020 will reach 3.995 billion U.S. dollars.

5) Atezolizumab

Trade name Tecentriq, anti-PD-L1 humanized IgG1κ monoclonal antibody (Fc engineered-non-glycosylated monoclonal antibody), was approved for marketing on May 18, 2016, and its indications are NSCLC/non-small cell lung cancer, bladder cancer ( Urothelial cancer) and other tumor diseases, the sellers are Roche (Genentech) and Chugai.

In 2020 (the fourth year after listing), sales will reach 3.276 billion U.S. dollars.

 

 

6. Products that have been on the market for 5 years and more than 10 years with a value of 3 billion USD

1) Tocilizumab

Trade name Actemra/Actemra JPN, anti-IL-6R humanized IgG1κ monoclonal antibody, the first batch in Japan in 2005 (approved in the United States on January 8, 2010), the indications are rheumatoid arthritis, cytokine release syndrome (CRS) ) And other immune/inflammatory diseases, the sellers are Roche (Genentech) and Chugai.

In the eighth year (2018) after the United States approved the listing, sales reached 3.189 billion U.S. dollars, and sales in 2020 were 4.668 billion U.S. dollars.

2) Pertuzumab

Trade name Perjeta, anti-HER2 Subdomain II humanized IgG1κ monoclonal antibody, was approved for marketing on June 8, 2012, and its indications are HER2-positive metastatic breast cancer and other tumor diseases. The vendors are Roche (Genentech) and Chugai.
In the seventh year (2019) after listing, sales reached 3.855 billion U.S. dollars, and sales in 2020 were 4.459 billion U.S. dollars.

3) Golimumab

The trade name is Simponi, an anti-TNFα fully human IgG1κ monoclonal antibody, approved for marketing on April 24, 2009. The indications are rheumatoid arthritis, psoriatic arthritis and other immune diseases. The vendors are J&J, Merck and M Tanabe BMS.
In the ninth year (2018) after listing, sales reached 3.302 billion U.S. dollars, and sales in 2020 were 3.081 billion U.S. dollars.

4) Omalizumab

Trade name Xolair, anti-IgE humanized IgG1κ monoclonal antibody, was approved for marketing on June 20, 2003. The indications are moderate to severe asthma, chronic idiopathic urticaria and other immune diseases. The sellers are Roche (Genentech) and Novartis .
In the 16th year after listing (2019), sales reached 3.173 billion U.S. dollars, and sales in 2020 were 3.281 billion U.S. dollars.

5) Abatacept

Trade name Orencia/Orencia SC, recombinant CTLA4-Fc fusion protein, was approved for marketing on December 23, 2005. The indications are rheumatoid arthritis, juvenile idiopathic arthritis and other immune diseases. The sellers are BMS and OnoPharmaceutical.
In the 14th year after listing (2019), sales reached US$3.155 billion, and sales in 2020 were US$3.157 billion (Note: only BMS sales data).

 

 

7. The stable products in the past 10 years

1) Ranibizumab

Trade name Lucentis, anti-VEGF humanized IgG1κ Fab fragment antibody, was approved for marketing on June 30, 2006. The indications are AMD (age-related macular degeneration), RVO (retinal vein occlusion) and other ophthalmic diseases. The seller is Roche ( Genentech) and Novartis.
In the past 10 years, annual sales have changed between US$3.106 and US$4.301 billion, with an average of US$3.691 billion, which is stable.

2) Natalizumab

Trade name Tysabri, anti-Alpha4/beta1/7 integrin humanized IgG4κ monoclonal antibody, was approved for marketing on November 23, 2014. The indications are MS (multiple sclerosis), CD (Crohn’s disease) and other immune diseases. The seller is Biogen IDEC.
In the past 10 years, annual sales have varied between US$1.230 and US$1.964 billion, with an average of US$1.774 billion.

3) Cetuximab

Trade name Erbitux, anti-EGFR (HER1) chimeric IgG1κ monoclonal antibody, was approved for marketing on February 12, 2004. It is indicated for EGFR-expressing metastatic colorectal cancer and other tumor diseases. The sellers are Eli Lilly and Merck KG.
In the past 10 years, annual sales have changed between 1.485 billion and 1.924 billion U.S. dollars, with an average of 1.685 billion U.S. dollars.

4) Palivizumab

Trade name Synagis, anti-RSV F protein humanized IgG1κ monoclonal antibody, was approved for marketing on June 19, 1998. The indication is for infants with abnormal bronchopulmonary development, premature infants and congenital heart disease with abnormal hemodynamics. Children’s prevention of RSV infection in the lower respiratory tract is sold by AstraZeneca and Abbvie.

In the past 10 years, annual sales have changed between 900 million and 1.425 billion US dollars (note: the 372 million in the figure in 2020 is only AstraZeneca sales data, not included in the calculation), with an average of 1.171 billion US dollars, which is stable.

5) Panitumumab

The trade name is Vectibix, an anti-EGFR (HER1) fully human IgG2κ monoclonal antibody. It was approved for marketing on September 27, 2006. Its indications are metastatic colorectal cancer (mCRC) and other tumor diseases. The sellers are Amgen and Takeda.
In the past 10 years, annual sales have changed between 384 million and 1.026 billion U.S. dollars, with an average of 712 million U.S. dollars.

 

8. Newly launched blockbuster products with rapid growth

1) Emicizumab

Trade name Hemlibra, anti-factor Ixa/factor X humanized IgG4 double antibody, indicated for hemophilia A (patients who develop resistance to anti-FVIII inhibitors), and sold by Roche (Genentech) and Chugai.
It was approved for listing on November 16, 2017, and its sales in 2019 reached 1.630 billion U.S. dollars, and it was promoted to the blockbuster ranks, reaching 2.654 billion U.S. dollars in 2020.

2) Durvalumab

The trade name is Imfinzi, an anti-PD-L1 fully human IgG1κ monoclonal antibody. The indication is locally advanced or metastatic urothelial cancer and other tumor diseases. The seller is Astrazeneca.
It was approved for listing on May 1, 2017, and its sales in 2019 reached 1.469 billion U.S. dollars, and it was promoted to the blockbuster ranks, reaching 2.042 billion U.S. dollars in 2020.

3) Ixekizumab

The trade name is Taltz, anti-IL17-A humanized IgG4 monoclonal antibody, the indication is adult moderate to severe plaque psoriasis and other immune diseases, the seller is EliLilly.
It was approved to go public on March 22, 2016, and its sales in 2019 reached 1.366 billion U.S. dollars, and it was promoted to the blockbuster ranks, reaching 1.789 billion U.S. dollars in 2020.

4) Risankizumab

The trade name is Skyrizi, anti-IL-23 humanized IgG1κ monoclonal antibody, the indication is moderate to severe psoriasis and other immune diseases, and the seller is AbbVie.
It was approved for listing on April 23, 2019, and its sales in 2020 will reach US$1.590 billion, making it a blockbuster.

5) Guselkumab

Trade name Tremfya, an anti-IL-23 p19 subunit fully human IgG1λ monoclonal antibody, is indicated for adult patients with moderate to severe plaque psoriasis and other immune diseases. The seller is J&J.
It was approved for listing on July 13, 2017, and its sales in 2019 reached US$1.012 billion, and it was promoted to the blockbuster ranks. In 2020, it was US$1.347 billion.

6) Mepolizumab

The trade name is Nucala, anti-IL-5 humanized monoclonal antibody, and its indications are immune diseases such as asthma and eosinophilia syndrome. The seller is GSK.
It was approved for listing on November 4, 2015, and its sales in 2020 will reach 1.276 billion U.S. dollars, making it a blockbuster.

7) Ravulizumab

The trade name is Ultomiris, anti-human complement C5 humanized IgG2/4κ monoclonal antibody, the indication is adult paroxysmal nocturnal hemoglobinuria (PNH), the seller is Alexion Pharm.
It was approved for listing on December 21, 2018, and its sales in 2020 will reach US$1.077 billion, making it a blockbuster.

8) Teprotumumab

Trade name Tepezza, anti-IGF-1R fully human IgG1 monoclonal antibody, indicated for the treatment of thyroid eye disease, and sold by Horizon and Genmab.
It was just approved for listing on January 21, 2020, and its sales that year reached 866 million U.S. dollars.

 

 

 

 

Analysis of 15-year sales data of antibody drugs (2006~2020)

Analysis of 15-year sales data of antibody drugs (2006~2020)

Analysis of 15-year sales data of antibody drugs (2006~2020)

(source:internet, reference only)


Disclarimer of medicaltrend.org